ZSZain Ul Abideen Shahid

Zain Ul Abideen Shahid

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Zain Ul Abideen Shahid has a total of 67 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Efficacy and Safety of Tradipitant for Motion Sickness—A GRADE Assessed Systematic Review and Meta-Analysis

    by Taha Ibrahim, Muhammad Burhan, Zain Ul Abideen Shahid, Ahila Ali, Muhammad Usman, Shaheer Bin Shafiq, Huzaifa Ul Haque Ansari, Muhammad Hasnain Azeem, Ahmed Ali, Jawaria Ibrahim, et al.

    Objective: To evaluate the efficacy and safety of tradipitant, a neurokinin-1 (NK1) receptor antagonist, for preventing motion sickness–induced vomiting. Data Sources: PubMed/MEDLINE, Embase, Scopus, and ClinicalTrials.gov were searched from inception through February 2026 without language or date resrictions. Study Selection and Data Extraction: Randomized controlled trials comparing tradipitant (85 or 170 mg) with placebo in adults with motion sickness were included. Two reviewers independently screened studies, extracted data, assessed risk of bias using Cochrane Risk of Bias 2, and evaluated certainty of evidence using Grading of Recommendations Assessment, Development, and Evaluation. Data Synthesis: Three randomized controlled trials (N = 808) were included. Tradipitant significantly reduced overall vomiting vs placebo (risk ratio [RR], 0.38; 95% confidence interval [CI], 0.30-0.48; I 2 = 0%) and improved the composite nausea/vomiting outcome (RR, 0.48; 95% CI, 0.35-0.65). Serious adverse events and somnolence were comparable between groups, although fatigue was more frequent with tradipitant (RR, 2.66; 95% CI, 1.02-6.93). Relevance to Patient Care and Clinical Practice in Comparison to Existing Drugs: Unlike antihistamines and anticholinergics, which are frequently limited by sedation and anticholinergic adverse effects, tradipitant significantly reduces motion-induced vomiting with minimal sedation and may benefit patients who do not respond to or cannot tolerate conventional therapies. Conclusions: Tradipitant significantly reduces motion sickness–induced vomiting while maintaining a favorable safety profile, supporting its role as an effective treatment option pending further comparative studies.

  • Efficacy and Safety of Filgotinib in Psoriatic Arthritis: A GRADE-Assessed Systematic Review and Meta-Analysis

    by Taha Ibrahim, Muhammad Burhan, Jawaria Ibrahim, Ahila Ali, Zain Ul Abideen Shahid, Muhammad Anzar, Muhammad Hanzalah Atif, Muhammed Khurshid Siddiqui, Arsalan Khan, Mahamud Hasan

    Background: Psoriatic arthritis (PsA) is a chronic inflammatory disease affecting musculoskeletal and cutaneous domains. Filgotinib, a preferential Janus kinase 1 inhibitor, has been investigated as a targeted oral therapy for PsA. Objectives: To evaluate the short-term efficacy and safety of filgotinib vs placebo in adults with PsA and assess the certainty of the evidence using Grading of Recommendations Assessment, Development, and Evaluation (GRADE). Design: The study was designed as a systematic review and meta-analysis of randomized controlled trials (RCTs). Data Sources and Methods: PubMed/MEDLINE, Embase, Scopus, and ClinicalTrials.gov were searched from inception to October 2025. Three RCTs involving 295 participants (173 receiving filgotinib and 122 receiving placebo) were included. Random-effects meta-analyses estimated risk ratios (RRs) for dichotomous outcomes and mean differences (MDs) for continuous outcomes. Efficacy was assessed at weeks 12 and 16, and certainty of evidence was evaluated using GRADE. Results: At week 16, filgotinib increased American College of Rheumatology 20% response (RR, 1.91, 95% CI, 1.38 to 2.64), minimal disease activity achievement (RR, 1.73, 95% CI, 1.05 to 2.85), and Psoriatic Arthritis Response Criteria response (RR, 1.59, 95% CI, 1.27 to 1.98). Psoriasis Area and Severity Index 75% response was also higher (RR, 2.68, 95% CI, 1.78 to 4.02). Psoriatic Arthritis Disease Activity Score improved (MD, −1.03, 95% CI, −1.42 to −0.63; 277 participants). No statistically significant differences were detected in serious adverse events (RR, 1.58, 95% CI, 0.29 to 8.69) or all-cause mortality (RR, 3.05, 95% CI, 0.13 to 73.42); these estimates were imprecise. Conclusion: Filgotinib demonstrated short-term efficacy across several PsA outcomes. However, 3 short-term RCTs with limited safety events cannot establish long-term safety or comparative effectiveness. Filgotinib is not approved for PsA, and its clinical role remains unestablished. Registration: PROSPERO CRD420251235155.

  • Efficacy and Safety of Baxdrostat in Hypertension: A GRADE-Assessed Systematic Review and Meta-Analysis of Randomized Controlled Trials

    by Muhammad Burhan, Zain Ul Abideen Shahid, Muhammad Abdullah Naveed, Nitin Wathore, Ziyan Ansari, Taha Ibrahim, Syed Huzaifa Alam Raza, Malika Abidi, Ayesha Irshad, Shiva Kumar, et al.

    Background: Baxdrostat, a selective aldosterone synthase inhibitor, has emerged as a novel therapy for uncontrolled or resistant hypertension; however, randomized controlled trials (RCTs) have shown variable results. Objective: To evaluate the efficacy and safety of baxdrostat compared with placebo or standard care in patients with uncontrolled or resistant hypertension. Methods: We conducted a Preferred Reporting Items for Systematic Reviews and Meta-analyses–compliant systematic review and meta-analysis of RCTs. PubMed, Embase, Scopus, Cochrane Library, and ClinicalTrials.gov were searched from inception to March 2026. Random-effects models were used to pool standardized mean differences (SMDs) and risk ratios (RRs). Certainty of evidence was assessed using Grading of Recommendations Assessment, Development, and Evaluation (GRADE). Results: Five RCTs (n = 1724) were included. Baxdrostat significantly reduced systolic blood pressure (SMD = −0.40; 95% CI = −0.59 to −0.22; P < .001) and diastolic blood pressure (SMD = −0.29; 95% CI = −0.47 to −0.11; P = .001), and increased achievement of blood pressure control P < .001). It reduced serum sodium (SMD = −0.63; 95% CI = −0.80 to −0.47) but increased serum potassium (SMD = 0.91; 95% CI = 0.77-1.05), hyperkalemia (RR = 10.22; 95% CI = 4.22-24.73), and hyponatremia (RR = 2.90; 95% CI = 1.82-4.61). A modest decline in eGFR was observed (SMD = −0.49; 95% CI = −0.65 to −0.34). Serious adverse events and mortality were not significantly different. Evidence certainty was moderate to high. Conclusion and Relevance: Baxdrostat significantly improves blood pressure control in patients with uncontrolled or resistant hypertension but increases the risk of hyperkalemia and other electrolyte disturbances. These findings strengthen the evidence for selective aldosterone synthase inhibition as a therapeutic approach for aldosterone-mediated hypertension and suggest that baxdrostat may provide an additional treatment option, particularly for patients who remain uncontrolled or cannot tolerate mineralocorticoid receptor antagonists. However, the increased risk of hyperkalemia and the limited duration of available trials highlight the need for careful electrolyte and renal monitoring and further studies evaluating long-term cardiovascular outcomes and comparisons with established therapies.

  • Open Access

    Doravirine and islatravir for HIV-1 treatment: A systematic review and meta-analysis with GRADE assessment

    by Muhammad Tayyab Azam, Muhammad Hussain Azam, Muhammad Arif Khan, Muhammad Hassan Azam, Zain Ul Abideen Shahid, Shahzad Ashraf, Syeda Momina Umer, Rabeea Arshad, Hasibullah Aminpoor, Hammad Javaid

    Background: Two-drug antiretroviral regimens are increasingly explored to simplify HIV-1 treatment while maintaining durable viral suppression. Doravirine combined with Islatravir (DOR/ISL) represents a novel non-integrase strand transfer inhibitor (non-INSTI) regimen. However, comprehensive synthesized evidence remains limited. Objectives: To systematically evaluate the efficacy and safety of fixed-dose Doravirine (100 mg) plus Islatravir (0.25 or 0.75 mg) for HIV-1 treatment in adults. Design: Systematic Review and Meta-Analysis. Data Sources and Methods: Comprehensive searches of PubMed, Embase, Scopus, Cochrane CENTRAL, ICTRP, and ClinicalTrials.gov were performed to identify RCTs evaluating Doravirine/Islatravir for HIV-1 treatment. The primary outcome was viral suppression (HIV-1 RNA 9 /L, p = 0.54). Statistically significant declines in CD4+ and lymphocyte counts were strictly restricted to the discontinued 0.75 mg dose. Overall adverse events and treatment discontinuations due to adverse events were comparable between groups. Conclusion: DOR/ISL provides non-inferior virologic efficacy compared with standard antiretroviral therapy with a favorable safety profile. The 0.25 mg Islatravir dose maintains antiviral efficacy while avoiding the immunologic declines observed with 0.75 mg dose, supporting its suitability as a simplified two-drug regimen. Registration: This review protocol was prospectively registered with PROSPERO ( CRD420261321479 ).

  • Efficacy and Safety of Aceclidine in Presbyopia, a Systematic Review and Meta -Analysis

    by Taha Ibrahim, Muhammad Burhan, Shaheer Bin Shafiq, Muhammad Junaid Razzak, Ayesha Ahmed Khan, Zain Ul Abideen Shahid, Mudassir Shahnawaz, Saud Ur Rehman, Jawaria Ibrahim, Hashem Abu Serhan

    Presbyopia, an age-related oculopathy in which a decline in accommodation capabilities results in difficulties in near vision tasks and hence compromises the performance of essential activities of ...

  • Efficacy and Safety of Olezarsen for the Management of Dyslipidemia: An Updated Systematic Review and Meta-Analysis of Randomized Controlled Trials

    by Muhammad Burhan, Taha Ibrahim, Muhammad Abdullah Naveed, Ziyan Ansari, Muhammad Ansab, Kisa Fatima, Saad Ashraf, Zain Ul Abideen Shahid, Ahmed Raza, Syed Huzaifa Alam Raza

  • Efficacy and Safety of Anrikefon (HSK21542) for Postoperative Pain. A Systematic Review and Meta-Analysis of Randomized Controlled Trials

    by Muhammad Tayyab Azam, Zain Ul Abideen Shahid, Muhammad Arif Khan, Shahzad Ashraf, Talha Aamir, Sufyan Ahmed, Saad Ashraf

    Postoperative pain remains a nearly universal experience, affecting up to 80% of surgical patients globally (1). Poorly controlled acute pain can delay recovery and also contributes to persistent p...

  • Open Access

    Efficacy and Safety of PrabotulinumtoxinA for the Treatment of Moderate-to-Severe Glabellar Lines: A GRADE-Assessed Systematic Review and Meta-Analysis

    by Zain Ul Abideen Shahid, Muhammad Hassan, Syeda Verisha Batool, Mehak Faisal, Sameer Tariq, Syeda Huda Fatima, Muhammad Hussain, Syeda Jazilah Faisal, Ghulam Taha Khan, Aleena Batool, et al.

    Glabellar lines are among the earliest and most visible signs of facial aging and can convey negative emotions while diminishing quality of life. PrabotulinumtoxinA is a 900 kDa formulation of botulinum toxin type A that provides targeted neuromuscular blockade to treat dynamic wrinkles through localized muscle relaxation. Individual trials have reported encouraging results, yet pooled estimates were needed to more accurately quantify efficacy and safety. The objective of this meta-analysis was to evaluate the efficacy and safety of prabotulinumtoxinA for the treatment of glabellar lines. The authors searched PubMed, Cochrane CENTRAL, Scopus, Embase, and ClinicalTrials.gov through May 2026 and identified 3 double-blind, placebo-controlled Phase III randomized controlled trials evaluating a 20 U dose of prabotulinumtoxinA vs placebo; 3 additional studies were included for qualitative safety analysis. In pooled random-effects analyses, prabotulinumtoxinA significantly increased the likelihood of achieving none-or-mild glabellar line severity scores (GLS score 0/1) at Day 30 (risk ratio [RR] = 19.24, 95% CI, 12.08-30.64; P < .01), demonstrated early treatment response at Day 2 (≥1-point improvement in GLS score: RR = 3.61, 95% CI, 2.52-5.19; P < .01) and showed greater sustainability through Day 150 (RR = 3.47, 95% CI, 2.13-5.65; P < .01). Safety outcomes, including treatment-emergent adverse events and specific safety endpoints, were comparable to placebo, with no significant differences. PrabotulinumtoxinA was well-tolerated and produced substantial and sustained improvement of glabellar lines. Further large-scale, long-term trials are needed to establish its durability and long-term safety profile. Level of Evidence: 2 (Therapeutic)